Venekra Detailed Instructions

1. Indications and Usage

Venetoclax is aBCL-2 inhibitor, indications:

For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). VeneclatIn combination with azacitidine, decitabine, or low-dose cytarabine Adults 75 years of age or older with newly diagnosed acute myeloid leukemia (AML) or with comorbidities that preclude the use of intensive induction chemotherapy.

2. Dosage and usage

See full prescribing information for recommended doses of venetoclax.

Oral once daily Veneclac tablets, take with food and water. Do not chew, crush, or break tablets.

Prevention of tumor lysis syndrome.

Three. Dosage form and strength

Tablets: 10mg, 50mg, 100mg (3)

Four. Contraindications

Concomitant use of strongCYP3Ainhibitors in CLL/SLL patients during the initial and ascending stages is prohibited.

Five. Warnings and Precautions

1.Tumor Lysis Syndrome:Predict tumor lysis syndrome; assess risk for all patients. Pre-administer anti-hyperuricemia medications and ensure adequate hydration. As the overall risk increases, more intensive measures (intravenous hydration, frequent monitoring, hospitalization) are used.

2.Neutropenia:Monitor blood cell counts. Interrupt dosing and resume the same or reduced dose. Consider supportive care measures.

3.Infection:Monitor for signs and symptoms of infection and treat promptly. For Grade 3 and Grade 4 infections, withhold dosing until resolution and continue dosing at the same or reduced dose.

4.Immunization:Do not receive live-attenuated vaccines before, during, or after treatment with veneclax until B cells have recovered.

5.Embryo-Fetal Toxicity:May cause harm to embryo-fetus. Inform women of reproductive potential of potential risks to the fetus and use effective contraceptive measures.

6.Except in controlled clinical trials, the use of venetoclaxin combination with bortezomib and dexamethasone is not recommended in the treatment of patients with multiple myeloma.

6. Adverse reactions

In CLL/SLL, veneclat is most effective when used in combination with obinutuzumab or rituximab or alone. Common adverse reactions (≥20%) are neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue and edema.

InAML, the most common adverse reactions (≥30%) when combined with azacitidine or decitabine or low-dose cytarabine were nausea, Diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, hemorrhage, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngeal pain, and hypotension.

7. Drug interactions

Strong or moderateCYP3Ainhibitors or P-gpinhibitors:Adjust the dose of veneclat.

Strong or moderateCYP3AInducers:Avoid coadministration.

P-gpSubstrate:Take at least 6 hours before venetoclax.

8. Use among specific groups of people

Lactation period:It is recommended that women not breastfeed.

Hepatic Impairment: In patients with severe hepatic impairment the dose of venetoclax is reduced by 50%.

The retail price of generic venetoclax100mg120 tablets is from 2 to more than 6 more than 1,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0

xa0

xa0